Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8973342 | 0.81 | MAOB (0.81) | NPC1RAB9AMAOBKMT2AMEN1 | |
| SCHEMBL9584535 | 0.80 | CYP1A2 (0.78) | CYP1A2NPC1GAACYP2D6MAPT | |
| SCHEMBL10184945 | 0.79 | CYP1A2 (0.57) | CYP1A2NPC1GAACYP2D6MAPT | |
| SCHEMBL19289588 | 0.78 | TP53 (0.54) | NPC1RAB9ASMN1; SMN2MAOB | |
| SCHEMBL27482073 | 0.77 | GCGR (0.50) | MAOB | |
| SCHEMBL9585652 | 0.76 | CYP1A2 (0.70) | CYP1A2NPC1GAACYP2D6MAPT | |
| SCHEMBL8396789 | 0.75 | MAOB (0.71) | NPC1RAB9AMAOBKMT2AEGLN1 | |
| SCHEMBL1161862 | 0.75 | GFER (0.64) | CYP1A2NPC1GAACYP2D6MAPT | |
| SCHEMBL13210593 | 0.75 | CYP1A2 (0.63) | CYP1A2CYP2C19RAB9ASMN1; SMN2TSHR | |
| SCHEMBL1976949 | 0.74 | CNR1 (0.47) | MAOBDEGS1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | CYP1A2 1822/4885NPC1 201/4885GAA 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.